Merck is celebrating its anniversary by conducting 350 charitable activities in around 60 countries

MerckMerck, a leading science and technology ­company, is celebrating its anniversary by conducting 350 charitable activities in around 60 countries. Taking responsibility has always been an integral part of the entrepreneurial approach of Merck and is one of its six values. On the occasion of its 350th anniversary, the company will further intensify its social engagement activities together with its employees.

"We have a long tradition of responsibility, it’s more than just lip service. That's why we want to share the great joy of our anniversary not only with our employees, but also with our local communities," said Walter Galinat, member of the Executive Board of Merck and responsible for the 350th anniversary celebrations. "We take on responsibility for society all over the world. Many of our employees and subsidiaries are involved in this effort, for instance through donations, collaborations with reliable partners and voluntary initiatives," he added.

The activities planned to take place throughout 2018 will focus on health as well as on education and culture. Here, Merck will leverage its 350 years of experience and curiosity, as well as its knowledge and expertise in the areas of health, science and technology. In addition to these efforts, the company also supports a wide array of charitable and environmental initiatives in the communities near its sites and provides disaster relief. The aim is to address challenges facing society, from fighting serious diseases and protecting natural resources to promoting aspiring young scientists.

The projects in the focus area of health are centered around developing local healthcare infrastructure, providing vocational and advanced training to medical staff and raising awareness of health issues. Founded in 2017, for instance, the Merck Foundation supports initiatives to improve the treatment of cancer patients in Africa. And in Guatemala, Merck is working with an organization that provides free healthcare to underprivileged communities and helps people with disabilities.

Within the focus area of education, particular emphasis is placed on sparking young people's interest in science. A prime example is the SPARK volunteer program, under which employees conduct scientific experiments with school children in an effort to arouse their curiosity. A large number of activities are also taking place in Darmstadt, where the company is headquartered. These include an exciting experiment afternoon for school students to mark the tenth anniversary of the Junior Laboratory at the Technical University of Darmstadt. In Indonesia, Merck is supporting the charitable organization Nara Kreatif, with which it is collaborating on environmental and educational projects. These include a school for 300 children in need, at which Merck employees are also volunteering.

Within the focus area of culture, Merck is often engaged in projects that transcend cultural borders, such as a literature initiative in Korea that encourages exchange between Germany and several Asian countries.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...